Matthew H. Kulke M.D's research while affiliated with Dana-Farber Cancer Institute and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publication (1)
BACKGROUND
Treatment with traditional cytotoxic chemotherapy regimens containing streptozocin or dacarbazine has resulted in only marginal benefit for patients with metastatic neuroendocrine tumors. The use of these regimens has been further limited by their potential toxicity. Gemcitabine is generally well tolerated and possesses demonstrated acti...
Citations
... Cormier et al. observed a response rate of 29% in 29 patients with previously untreated SCLC [33], while van der Lee et al. found an overall response rate of 13% in a collective of 41 patients with pre-treated, limited-or extensive-stage SCLC [34]. In 2004, Kulke and colleagues examined a collective of 18 patients with metastatic neuroendocrine tumors, of which seven presented pancreatic primaries, and found disease stabilization in 65% of them following monotherapy with Gemcitabine, although no radiological or biochemical response was achieved [35]. All of the studies concurringly found Gemcitabine to be well tolerated, with a favorable side-effects profile [33][34][35]. ...
